The aim of this study was to assess the safety and efficacy of Janus kinase inhibitors (JAKi), in the management of key clinical domains of PsA including peripheral arthritis, psoriasis, enthesitis and dactylitis. To read the full article, choose Open Athens “Institutional Login” and search for “Midlands Partnership”.